Skip to main content

Table 1 Factors associated with VRE detection in cases and controls (Univariate analysis)

From: Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study

Variables Cases Controls Unadjusted OR P value
Participants 58 116 - -
Age ≥ 65 (years) 35 (60.3%) 56 (48.2%) 1.63 (0.82 to 3.26) 0.13
Male 36 (62.1%) 74 (63.8%) 0.92 (0.46 to 1.88) 0.82
Antibiotics     
Exposure to any antibiotic 45 (77.6%) 55 (47.4%) 3.83 (1.79 to 8.54) <0.001
Meropenem 8 (13.8%) 2 (1.7%) 9.12 (1.71 to 89.92) 0.001
Antibiotics other than meropenem 39 (67.2%) 54 (46.5%) 4.5 (2.06 to 10.71) 0.001
Vancomycin 13 (22.4%) 19 (16.38%) 1.47 (0.61 to 3.46) 0.33
Teicoplanin 2 (3.4%) 2 (1.7%) 2.03 (0.14 to 28.63) 0.47
Any cephalosporin 19 (32.8%) 32 (27.6%) 1.27 (0.60 to 2.66) 0.47
Ceftriaxone 11 (18.9%) 24 (20.7%) 0.89 (0.36 to 2.11) 0.78
Cefotaxime 2 (3.4%) 0 - -
Ceftazidime 5 (8.6%) 4 (3.4%) 2.64 (0.54 to 13.79) 0.14
Cefepime 1 (1.7%) 6 (5.2%) 0.32 (0.01 to 2.76) 0.27
Metronidazole 5 (8.6%) 19 (16.4%) 0.48 (0.13 to 1.43) 0.16
Ciprofloxacin 11 (18.9%) 9 (7.8%) 2.78 (0.96 to 8.11) 0.03
Ticarcillin-clavulanate 11 (18.9%) 12 (10.3%) 2.02 (0.74 to 5.41) 0.11
Ampicillin 1 (1.7%) 3 (2.6%) 0.66 (0.01 to 8.45) 0.72
Gentamicin 2 (3.4%) 9 (7.8%) 0.42 (0.04 to 2.16) 0.27
Piperacillin-tazobactam 5 (8.6%) 3 (2.6%) 3.55 (0.65 to 23.53) 0.07
Other factors     
ICU admission 18 (31.1%) 26 (22.4%) 1.55 (0.71 to 3.33) 0.21
Within 2 rooms of positive case 30 (62.5%) 54 (65.8%) 0.86 (0.38 to 1.94) 0.69
On same side as positive case 48 (82.8%) 83 (77.6%) 1.38 (0.57 to 3.53) 0.43
Diarrhoea 12 (21.1%) 11 (9.5%) 2.54 (0.94 to 6.85) 0.03
Length of stay (Median days) 11.5 (7–30) 6.0 (3–13) - <0.001
Length of stay ≥7 days 43 (74.2%) 43 (37.1%) 4.86 (2.30 to 10.51) <0.001